Business
Scilex Holding Company announces the State of Indiana Medicaid will add Elyxyb as a preferred agent to its preferred drug list (PDL) effective October 1, 2023
PALO ALTO, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company
About this update from Scilex Holding Company
[{"type":"text","content":"PALO ALTO, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced the State of Indiana Medicaid will add Elyxyb as a preferred agent to its Preferred Drug List (“PDL”) effective October 1, 2023. As Indiana is a Single PDL State, where the five Indiana Managed Medicaid plans (Anthem, CareSource, MDwise, Managed Health Services (MHS), and UnitedHealthcare) must follow the State PDL, this change improves access to Elyxyb for all eligible patients under the Indiana Medicaid umbrella, the combined traditional Medicaid and Managed Medicaid populations, totaling approximately 1.2M lives, between the ages of 18-64. Under the new terms, Elyxyb will be Preferred with the following prior authorization (PA) criteria: Migraine Dx, 18 & OlderTrial and failure of 1 preferred triptan or contraindication to triptansElyxyb will have a QL of 6 bottles. “We are pleased to announce our first Elyxyb managed health care win with the Medicaid plan in Indiana, which we believe is an important step to expand utilization of Elyxyb throughout the U.S. Importantly, our diversified portfolio of unique, leading programs will increasingly allow us to offer patients complementary and standalone opioid-sparing outpatient pain management solutions,” said Jaisim Shah, Chief Executive Officer of Scilex Holding Company. About Scilex Holding Company Scilex Holding Company is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Scilex is uncompromising in its focus to become the global pain management leader committed to social, environmental, economic, and ethical principles to responsibly develop pharmaceutical products to maximize quality of life. Results from the Phase III Pivotal Trial C.L.E.A.R. Program for SEMDEXATM, its novel, non-opioid product for the treatment of lumbosacral radicular pain (sciatica), were announced in March 2022. Scilex participated in the type C meeting for purposes of pre-NDA discussion with the FDA and is pending official minutes in writing from the FDA. Scilex targets indications with ...